Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
ChemMedChem ; 3(10): 1604-15, 2008 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-18792034

RESUMEN

The development of resistance has rendered several antibiotics clinically ineffective, and there is an urgent medical need for potent and safe antibacterials with a novel and valid mode of action. To avoid cross-resistance, they should preferably inhibit targets that are not addressed by established antibiotics. In this respect, 6-anilinouracils represent a promising lead structure. They target the Gram-positive DNA polymerase IIIC, a target that is associated with a bactericidal mode of action. Moreover, they have no cross-resistance to marketed antibiotics. This paper describes the synthesis and biological characterization of structurally novel anilinouracils, some of which display potent in vivo efficacy in murine models of bacterial septicemia.


Asunto(s)
Antibacterianos/síntesis química , Antibacterianos/farmacología , ADN Polimerasa III/antagonistas & inhibidores , Uracilo/análogos & derivados , Animales , Antibacterianos/química , Células Cultivadas , ADN Polimerasa III/metabolismo , Diseño de Fármacos , Humanos , Concentración 50 Inhibidora , Ratones , Pruebas de Sensibilidad Microbiana , Modelos Animales
2.
Bioorg Med Chem Lett ; 18(11): 3215-8, 2008 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-18468893

RESUMEN

3-Substituted 6-anilinouracils, presently the most promising class of inhibitors of the bacterial DNA polymerase in Gram-positive bacteria, have been prepared by a general and straightforward three-step procedure starting from a readily available 1-benzyloxymethyl-protected derivative of 6-chlorouracil.


Asunto(s)
Compuestos de Anilina/síntesis química , Antibacterianos/síntesis química , ADN Polimerasa III/antagonistas & inhibidores , Inhibidores Enzimáticos/síntesis química , Bacterias Grampositivas/efectos de los fármacos , Uracilo/análogos & derivados , Uracilo/síntesis química , Compuestos de Anilina/farmacología , Antibacterianos/farmacología , Inhibidores Enzimáticos/farmacología , Pruebas de Sensibilidad Microbiana , Estructura Molecular , Relación Estructura-Actividad , Uracilo/farmacología
3.
Microbiology (Reading) ; 153(Pt 7): 2093-2103, 2007 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-17600054

RESUMEN

(-)-Epicatechin gallate (ECg), a component of green tea, sensitizes meticillin-resistant Staphylococcus aureus (MRSA) to beta-lactam antibiotics, promotes staphylococcal cell aggregation and increases cell-wall thickness. The potentiation of beta-lactam activity against MRSA by ECg was not due to decreased bacterial penicillin-binding protein (PBP) 2a expression or ECg binding to peptidoglycan. A 5-10 % reduction in peptidoglycan cross-linking was observed. Reduced cross-linking was insufficient to compromise the integrity of the cell wall and no evidence of PBP2a activity was detected in the muropeptide composition of ECg-grown cells. ECg increased the quantity of autolysins associated with the cell wall, even though the cells were less susceptible to Triton X-100-induced autolysis than cells grown in the absence of ECg. ECg promoted increased lysostaphin resistance that was not due to alteration of the pentaglycine cross-bridge configuration or inhibition of lysostaphin activity. Rather, decreased lysostaphin susceptibility was associated with structural changes to wall teichoic acid (WTA), an acid-labile component of peptidoglycan. ECg also promoted lipoteichoic acid (LTA) release from the cytoplasmic membrane. It is proposed that ECg reduces beta-lactam resistance in MRSA either by binding to PBPs at sites distinct from the penicillin-binding site or by intercalation into the cytoplasmic membrane, displacing LTA from the phospholipid palisade. Thus, ECg-mediated alterations to the physical nature of the bilayer will elicit structural changes to WTA that result in modulation of the cell-surface properties necessary to maintain the beta-lactam-resistant phenotype.


Asunto(s)
Catequina/análogos & derivados , Pared Celular/efectos de los fármacos , Peptidoglicano/metabolismo , Staphylococcus aureus/efectos de los fármacos , Resistencia betalactámica/efectos de los fármacos , Catequina/química , Catequina/farmacología , Pared Celular/química , Pared Celular/enzimología , Proteínas de Unión a las Penicilinas , Staphylococcus aureus/genética , Staphylococcus aureus/crecimiento & desarrollo , Resistencia betalactámica/fisiología
4.
Antimicrob Agents Chemother ; 49(3): 987-95, 2005 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-15728893

RESUMEN

Novel N-3-alkylated 6-anilinouracils have been identified as potent and selective inhibitors of bacterial DNA polymerase IIIC, the enzyme essential for the replication of chromosomal DNA in gram-positive bacteria. A nonradioactive assay measuring the enzymatic activity of the DNA polymerase IIIC in gram-positive bacteria has been assembled. The 6-anilinouracils described inhibited the polymerase IIIC enzyme at concentrations in the nanomolar range in this assay and displayed good in vitro activity (according to their MICs) against staphylococci, streptococci, and enterococci. The MICs of the most potent derivatives were about 4 microg/ml for this panel of bacteria. The 50% effective dose of the best compound (6-[(3-ethyl-4-methylphenyl)amino]-3-{[1-(isoxazol-5-ylcarbonyl)piperidin-4-yl]methyl}uracil) was 10 mg/kg of body weight after intravenous application in a staphylococcal sepsis model in mice, from which in vivo pharmacokinetic data were also acquired.


Asunto(s)
Antibacterianos/farmacología , ADN Polimerasa III/antagonistas & inhibidores , Inhibidores Enzimáticos/farmacología , Bacterias Grampositivas/enzimología , Animales , ADN/biosíntesis , Perros , Inhibidores Enzimáticos/farmacocinética , Femenino , Bacterias Grampositivas/efectos de los fármacos , Masculino , Ratones , Pruebas de Sensibilidad Microbiana , Ratas , Ratas Wistar , Staphylococcus aureus/efectos de los fármacos , Staphylococcus aureus/enzimología , Relación Estructura-Actividad
5.
Antimicrob Agents Chemother ; 48(10): 3749-57, 2004 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-15388430

RESUMEN

The cell wall composition and autolytic properties of passage-selected glycopeptide-intermediate Staphylococcus aureus (GISA) isolates and their parent strains were studied in order to investigate the mechanism of decreased vancomycin susceptibility. GISA had relatively modest changes in peptidoglycan composition involving peptidoglycan interpeptide bridges and somewhat decreased cross-linking compared to that of parent strains. The cell wall phosphorus content of GISA strains was lower than that of susceptible parent strains, indicating somewhat lower wall teichoic acid levels in the GISA strains. Similar to whole cells, isolated crude cell walls retaining autolytic activity of GISA had drastically reduced autolytic activity compared to that of parent strains, and this arose early in the development of the GISA phenotype. This was due to an alteration in the autolytic enzymes of GISA as revealed by normal susceptibility of GISA-purified cell walls to parental strain autolysin extract and lower activity and altered peptidoglycan hydrolase activity profiles in GISA autolysin extracts compared to those of parent strains. Northern blot analysis indicated that expression of atl, the major autolysin gene, was significantly downregulated in a GISA strain compared to that of its parent strain. In contrast to whole cells, which showed decreased lysostaphin susceptibility, purified cell walls of GISA showed increased susceptibility to lysostaphin. We suggest that in our GISA strains, decreased autolytic activity is involved in the tolerance of vancomycin and the activities of endogenous autolysins are important in conferring sensitivity to lysostaphin on whole cells.


Asunto(s)
Antibacterianos/farmacología , Bacteriólisis/efectos de los fármacos , Pared Celular/química , Glicopéptidos/farmacología , Lisostafina/farmacología , Staphylococcus aureus/efectos de los fármacos , Northern Blotting , Cromatografía Líquida de Alta Presión , Citoplasma/química , Citoplasma/metabolismo , Peptidoglicano/farmacología , Fósforo/química , Ácidos Teicoicos/metabolismo , Resistencia a la Vancomicina
6.
FEMS Microbiol Lett ; 221(1): 73-9, 2003 Apr 11.
Artículo en Inglés | MEDLINE | ID: mdl-12694913

RESUMEN

Group B streptococcus (GBS) is the major cause of bacterial sepsis and meningitis in neonates and poses a significant threat to parturient women. Recently, we identified in GBS the polypeptide PcsB, which is a protein required for cell separation of GBS, and which is also involved in the antibiotic sensitivity of these bacteria. In the present study, the introduction of the pcsB-carrying plasmid pATpcsB into the PcsB-deficient GBS mutant Sep1 restored the phenotype and the antibiotic susceptibility of this strain to that of the GBS wild-type. Although Northern blots revealed a four- to five-fold increased transcription of pcsB in pATpcsB-carrying GBS strains, overexpression of pcsB did not result in higher amounts of PcsB in the cell wall and in the culture supernatant of GBS, indicating regulatory mechanisms that control the translation or secretion of PcsB in these bacteria. In the culture supernatant of mutant Sep1 significant amounts of enolase were identified. As this protein was also present in extracts of cell wall-bound proteins from the GBS wild-type, it can be speculated that GBS can translocate enolase across the cytoplasmic membrane. Northern blot analysis exhibited similar expression of the enolase gene in the GBS strains 6313 and Sep1, indicating that mutant Sep1 is impaired in the anchoring of this protein to its cell wall.


Asunto(s)
Proteínas Bacterianas/metabolismo , Proteínas de Ciclo Celular/metabolismo , Mutación , Streptococcus agalactiae/genética , Secuencia de Aminoácidos , Aminoácidos/análisis , Antibacterianos/farmacología , Proteínas Bacterianas/genética , Proteínas de Ciclo Celular/genética , Pared Celular/química , Pared Celular/metabolismo , Prueba de Complementación Genética , Lactamas/farmacología , Pruebas de Sensibilidad Microbiana , Datos de Secuencia Molecular , Análisis de Secuencia de ADN , Streptococcus agalactiae/efectos de los fármacos , Streptococcus agalactiae/metabolismo , Combinación Trimetoprim y Sulfametoxazol/farmacología
7.
Antimicrob Agents Chemother ; 47(2): 568-76, 2003 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-12543661

RESUMEN

Many VISA (vancomycin intermediately resistant Staphylococcus aureus) strains are characterized by increased cell wall biosynthesis and decreased cross-linking of the peptide side chains, leading to accumulation of free D-alanyl-D-alanine termini in the peptidoglycan, which act as false target sites for vancomycin. A spontaneous mutant of methicillin-resistant VISA strain SA137/93A (vancomycin MIC [E-test], 8 micro g/ml), called SA137/93G, showed increased resistance to vancomycin (MIC [E-test], 12 micro g/ml). Analysis of the resistance profile of the mutant revealed a loss of beta-lactam resistance with a concomitant increase in resistance to glycopeptides. In both strains, cell wall thickness was 1.4-fold greater than that of control isolates. However, cross-linking of the cell wall was drastically lower in SA137/93A than in SA137/93G. The sensitivity of strain SA137/93G to beta-lactams was due to loss of the beta-lactamase plasmid and a deletion that comprises 32.5 kb of the methicillin resistance cassette SCCmec, as well as 65.4 kb of chromosomal DNA. A spontaneous mutant of SA137/93G with higher sensitivity to vancomycin displayed a cell wall profile similar, in some respects, to that of an fmhB mutant. Results described here and elsewhere show that the only feature common to all VISA strains is a thickened cell wall, which may play a central role in the vancomycin resistance mechanism.


Asunto(s)
Antibacterianos/farmacología , Staphylococcus aureus/genética , Vancomicina/farmacología , Pared Celular/efectos de los fármacos , Electroforesis en Gel de Campo Pulsado , Resistencia a la Meticilina , Pruebas de Sensibilidad Microbiana , Fenotipo , Staphylococcus aureus/clasificación , Staphylococcus aureus/efectos de los fármacos , Resistencia a la Vancomicina/genética
8.
Microbiology (Reading) ; 148(Pt 10): 3245-3254, 2002 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-12368458

RESUMEN

Group B streptococcus (GBS) is surrounded by a capsule. However, little is known about peptidoglycan metabolism in these bacteria. In the present study, a 65 kDa protein was isolated from the culture supernatant of GBS and N-terminally sequenced, permitting isolation of the corresponding gene, termed bsp. The bsp gene was located close to another gene, designated femH, and reverse transcription-PCR revealed a bicistronic transcriptional organization for both genes. The Bsp protein was detected in the culture supernatant from 31 tested clinical isolates of GBS, suggesting a wide distribution of Bsp in these bacteria. Overexpression of bsp resulted in lens-shaped GBS cells, indicating a role for bsp in controlling cell morphology. Insertional disruption of femH resulted in a reduction of the L-alanine content of the peptidoglycan, suggesting that femH is involved in the incorporation of L-alanine residues in the interpeptide chain of the peptidoglycan of GBS.


Asunto(s)
Alanina/análisis , Proteínas Bacterianas/metabolismo , Pared Celular/química , Peptidoglicano/análisis , Streptococcus agalactiae/ultraestructura , Proteínas Bacterianas/química , Proteínas Bacterianas/genética , Medios de Cultivo Condicionados , Eliminación de Gen , Humanos , Recién Nacido , Lactamas/farmacología , Pruebas de Sensibilidad Microbiana , Microscopía Electrónica de Rastreo , Datos de Secuencia Molecular , Mutagénesis Insercional , Análisis de Secuencia de ADN , Streptococcus agalactiae/efectos de los fármacos , Streptococcus agalactiae/crecimiento & desarrollo , Streptococcus agalactiae/metabolismo
9.
Antimicrob Agents Chemother ; 46(1): 75-81, 2002 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-11751114

RESUMEN

A vancomycin-resistant Staphylococcus aureus mutant, COL-VR1 (MIC, 16 microg/ml), was isolated from methicillin-resistant S. aureus COL by exposure to vancomycin. COL-VR1 also showed decreased susceptibility to teicoplanin (8-fold), methicillin (2-fold), macarbomycin (8-fold), and moenomycin (16-fold). Macarbomycin and moenomycin are thought to directly inhibit transglycosylase activity. Characterization of the mutant revealed a thickened cell wall and suppression of penicillin-induced lysis, although the amounts of the five penicillin-binding proteins (PBPs 1, 2, 3, 4, and 2') and the profiles of peptidoglycan hydrolases were not altered. Analysis of muropeptide profile and glycan chain length distribution by reversed-phase high-pressure liquid chromatography revealed slightly decreased peptide cross-linking and an increased average glycan chain length compared to those of the parent. These results together suggest that a transglycosylase activity was enhanced in the mutant. This may represent a novel mechanism of glycopeptide resistance in S. aureus.


Asunto(s)
Oligosacáridos/farmacología , Polisacáridos/metabolismo , Staphylococcus aureus/efectos de los fármacos , Resistencia a la Vancomicina/fisiología , Aminoglicósidos , Antibacterianos/farmacología , Recuento de Colonia Microbiana , Pruebas de Sensibilidad Microbiana , Microscopía Electrónica , Mutación , Peptidoglicano/análisis , Polisacáridos/química , Staphylococcus aureus/genética , Staphylococcus aureus/metabolismo , Staphylococcus aureus/ultraestructura
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...